← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Aditxt, Inc. (ADTX) 10-Year Financial Performance & Capital Metrics

ADTX • • Industrial / General
HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring
AboutAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Show more
  • Revenue $134K -79.2%
  • EBITDA -$27M -6.8%
  • Net Income -$34M -6.4%
  • EPS (Diluted) -346053.00 +65.4%
  • Gross Margin -367.95% -2026.0%
  • EBITDA Margin -20335.67% -414.1%
  • Operating Margin -20796.36% -414.8%
  • Net Margin -25708.85% -412.2%
  • ROE -283.12% +7.1%
  • ROIC -86.1% +11.9%
  • Debt/Equity 0.84 -26.4%
  • Interest Coverage -3.78 +7.2%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 0 (bottom 0%)
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y8.45%
TTM-97.2%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-5.1%

EPS CAGR

10Y-
5Y-
3Y-
TTM99.98%

ROCE

10Y Avg-238.31%
5Y Avg-238.31%
3Y Avg-219.44%
Latest-203.2%

Peer Comparison

Diagnostics & Immune Monitoring
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TECHBio-Techne Corporation10.9B69.96152.095.23%6.41%3.97%2.35%0.23
SPRYARS Pharmaceuticals, Inc.1.1B11.09142.002970.63%-56.06%-54.21%1.18%0.00
VCYTVeracyte, Inc.3.24B41.00132.2623.46%6.12%2.41%1.97%0.04
CSBRChampions Oncology, Inc.99.56M7.1721.7313.54%4.32%59.65%7.03%1.62
MDXGMiMedx Group, Inc.851.59M5.7520.548.52%10.38%17.09%7.58%0.13
LTRNLantern Pharma Inc.39.26M3.51-0.00-197.36%0.01
SEERSeer, Inc.107.44M1.91-1.37-8.13%-486.02%-29.19%0.08
IMDXInsight Molecular Diagnostics Inc.189.76M6.62-1.4225.15%-13.81%-14.81%

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0000105.03K933.72K645.18K133.99K
Revenue Growth %-----7.89%-0.31%-0.79%
Cost of Goods Sold+00017.77K77.98K766.78K756.84K627.47K
COGS % of Revenue----0.74%0.82%1.17%4.68%
Gross Profit+000-17.77K27.05K166.94K-111.66K-493K
Gross Margin %----0.26%0.18%-0.17%-3.68%
Gross Profit Growth %----2.52%5.17%-1.67%-3.42%
Operating Expenses+212.99K5.61M5.87M8.85M41.96M25.65M25.95M27.37M
OpEx % of Revenue----399.51%27.47%40.22%204.28%
Selling, General & Admin212.99K5.08M5.7M7.92M22.42M17.84M18.88M16.48M
SG&A % of Revenue----213.45%19.1%29.26%123.03%
Research & Development0525K175.44K937.97K5.04M7.27M7.07M10.89M
R&D % of Revenue----48.01%7.78%10.96%81.25%
Other Operating Expenses000014.5M544.03K00
Operating Income+-213K-5.61M-5.87M-8.87M-41.94M-25.48M-26.06M-27.86M
Operating Margin %-----399.25%-27.29%-40.4%-207.96%
Operating Income Growth %--25.33%-0.05%-0.51%-3.73%0.39%-0.02%-0.07%
EBITDA+638.94K00-8.85M-41.46M-24.94M-25.52M-27.25M
EBITDA Margin %-----394.72%-26.71%-39.55%-203.36%
EBITDA Growth %--1%---3.68%0.4%-0.02%-0.07%
D&A (Non-Cash Add-back)851.94K5.61M5.87M17.77K476.24K535.98K542.58K617.25K
EBIT-213K-5.61M-5.83M-8.84M-44.43M-25.36M-26M-27.66M
Net Interest Income+000-309.52K-1.94M-2.23M-6.38M-7.36M
Interest Income001.93K5633.1K57.35K10.17K1.45K
Interest Expense079.77K1.93K310.08K1.94M2.29M6.39M7.36M
Other Income/Expense0-79.77K43.07K-277.02K-4.44M-2.17M-6.33M-7.16M
Pretax Income+-852K-5.69M-5.83M-9.15M-46.37M-27.65M-32.39M-35.02M
Pretax Margin %-----441.49%-29.61%-50.2%-261.37%
Income Tax+-852K0000000
Effective Tax Rate %0.25%1%1%1%1%1%1%0.98%
Net Income+-213K-5.69M-5.83M-9.15M-46.37M-27.65M-32.38M-34.45M
Net Margin %-----441.49%-29.61%-50.19%-257.09%
Net Income Growth %--25.71%-0.02%-0.57%-4.07%0.4%-0.17%-0.06%
Net Income (Continuing)-213K-5.69M-5.83M-9.15M-46.37M-27.65M-32.39M-35.02M
Discontinued Operations00000000
Minority Interest000000-9.61K-583.18K
EPS (Diluted)+-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-346053.00
EPS Growth %--25.71%-0.02%0.37%-2.44%0.88%0.82%1%
EPS (Basic)-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-999999.00-346053.00
Diluted Shares Outstanding0000000117
Basic Shares Outstanding0000000117
Dividend Payout Ratio--------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+25K115.71K4.09K11.03M9.42M4.74M6.91M2M
Cash & Short-Term Investments25K115.71K4.09K10.5M7.87M2.77M97.1K833.03M
Cash Only25K115.71K4.09K10.5M7.87M2.77M97.1K833.03K
Short-Term Investments0000000832.2M
Accounts Receivable0000589.84K527.96K5.85M1.15M
Days Sales Outstanding----2.05K206.393.31K3.14K
Inventory0000494.7K950.09K745.5K11.24K
Days Inventory Outstanding----2.32K452.26359.536.54
Other Current Assets000384.69K000-885.71M
Total Non-Current Assets+00119.44K2.06M7.25M5.99M37.67M30.14M
Property, Plant & Equipment0001.67M6.36M5.48M4.1M2.77M
Fixed Asset Turnover----0.02x0.17x0.16x0.05x
Goodwill00000000
Intangible Assets000321K214K107K9.44K6.11K
Long-Term Investments00000022.28M27.28M
Other Non-Current Assets00119.44K72.3K668.79K405.37K11.28M-310.19K
Total Assets+25K115.71K123.53K13.1M16.66M10.74M44.58M32.14M
Asset Turnover----0.01x0.09x0.01x0.00x
Asset Growth %-3.63%0.07%105.02%0.27%-0.36%3.15%-0.28%
Total Current Liabilities+59.9K1.65M2.98M1.23M3.61M3.64M25.89M23.41M
Accounts Payable8.57K1.06M1.85M241.61K1.58M1.96M8.55M10.19M
Days Payables Outstanding---4.96K7.37K932.284.13K5.93K
Short-Term Debt0163.6K165.6K587.59K700.43K409.98K16.18M5.8M
Deferred Revenue (Current)0000-1000K-1000K00
Other Current Liabilities51.33K006.54K1.76M2.15M158.61K4.48M
Current Ratio0.42x0.07x0.00x8.99x2.61x1.30x0.27x0.09x
Quick Ratio0.42x0.07x0.00x8.99x2.47x1.04x0.24x0.08x
Cash Conversion Cycle-----3.01K-273.63-455.04-2.78K
Total Non-Current Liabilities+25K1.22M0858.06K2.88M1.89M2.64M450.87K
Long-Term Debt0000110.04K000
Capital Lease Obligations000858.06K2.77M1.89M1.04M436.35K
Deferred Tax Liabilities00000000
Other Non-Current Liabilities25K000001.6M14.52K
Total Liabilities84.9K1.65M2.98M2.09M6.48M5.53M28.53M23.86M
Total Debt+0163.6K165.6K1.84M4.72M3.38M18.22M6.92M
Net Debt-25K47.89K161.51K-8.66M-3.15M613.22K18.12M6.09M
Debt / Equity---0.17x0.46x0.65x1.14x0.84x
Debt / EBITDA--------
Net Debt / EBITDA-0.04x-------
Interest Coverage--70.32x-3041.86x-28.61x-21.63x-11.15x-4.08x-3.78x
Total Equity+-59.9K-1.54M-2.85M11.01M10.18M5.21M16.05M8.29M
Equity Growth %--24.65%-0.86%4.86%-0.08%-0.49%2.08%-0.48%
Book Value per Share---0.850.231.2112.1771060.39
Total Shareholders' Equity-59.9K-1.54M-2.85M11.01M10.18M5.21M16.06M8.87M
Common Stock7.1K7.53K3.92K13.08K44.53K4.31K1.32K130
Retained Earnings-212.99K-5.9M-11.73M-20.88M-67.35M-95.04M-127.74M-168.09M
Treasury Stock00-189.63K-201.6K-201.6K-201.6K-201.6K-201.6K
Accumulated OCI00000000
Minority Interest000000-9.61K-583.18K

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+0-386.26K-464.35K-7.22M-22.28M-22.39M-18.58M-16.76M
Operating CF Margin %-----212.1%-23.98%-28.79%-125.1%
Operating CF Growth %---0.2%-14.55%-2.09%-0.01%0.17%0.1%
Net Income-851.94K-5.69M-5.83M-9.15M-46.37M-27.65M-32.38M-34.45M
Depreciation & Amortization00017.77K476.24K535.98K542.58K617.25K
Stock-Based Compensation612.34K3.52M4.23M3.19M4.64M3.13M1.4M6.75M
Deferred Taxes000017M000
Other Non-Cash Items34.26K350.51K0300K1.85M2.08M2.76M3.23M
Working Capital Changes205.34K1.43M1.13M-1.58M129.97K-493.44K9.1M7.09M
Change in Receivables0000-89.84K-36.77K119.64K364.89K
Change in Inventory0000-494.7K-455.4K204.59K734.26K
Change in Payables01.05M601.61K-1.48M1.33M412.96K6.65M5.1M
Cash from Investing+000-170.63K-16.31M-241.92K-14.41K-5M
Capital Expenditures000-170.63K-1.02M-367.08K-14.41K0
CapEx % of Revenue----9.67%0.39%0.02%-
Acquisitions--------
Investments--------
Other Investing0000-15.29M125.16K00
Cash from Financing+100K476.97K352.73K17.89M35.95M17.53M16.55M22.5M
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid00000000
Share Repurchases--------
Other Financing100K-273.75K-119.44K-45K2.53M709.08K627.86K5.58M
Net Change in Cash--------
Free Cash Flow+0-386.26K-464.35K-7.39M-23.29M-22.76M-18.59M-16.76M
FCF Margin %-----221.77%-24.37%-28.82%-125.1%
FCF Growth %---0.2%-14.92%-2.15%0.02%0.18%0.1%
FCF per Share----0.57-0.52-5.29-14.10-143744.38
FCF Conversion (FCF/Net Income)-0.07x0.08x0.79x0.48x0.81x0.57x0.49x
Interest Paid00000000
Taxes Paid00000000

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)----224.26%-437.62%-359.39%-304.72%-283.12%
Return on Invested Capital (ROIC)-----670.76%-297.44%-97.77%-86.1%
Gross Margin----25.76%17.88%-17.31%-367.95%
Net Margin-----44148.56%-2961.29%-5018.92%-25708.85%
Debt / Equity---0.17x0.46x0.65x1.14x0.84x
Interest Coverage--70.32x-3041.86x-28.61x-21.63x-11.15x-4.08x-3.78x
FCF Conversion-0.07x0.08x0.79x0.48x0.81x0.57x0.49x
Revenue Growth-----788.96%-30.9%-79.23%

Frequently Asked Questions

Growth & Financials

Aditxt, Inc. (ADTX) reported $0.0M in revenue for fiscal year 2024.

Aditxt, Inc. (ADTX) saw revenue decline by 79.2% over the past year.

Aditxt, Inc. (ADTX) reported a net loss of $42.2M for fiscal year 2024.

Dividend & Returns

Aditxt, Inc. (ADTX) has a return on equity (ROE) of -283.1%. Negative ROE indicates the company is unprofitable.

Aditxt, Inc. (ADTX) had negative free cash flow of $22.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.